Veeva Systems

Veeva Becomes First Public Company to Convert to a Public Benefit Corporation

Thursday, January 14, 2021 - 7:03am

With shareholder approval, Veeva will become a public benefit corporation on Feb. 1, 2021, making it the first publicly traded company and largest-ever to convert to a PBC.

Key Points: 
  • With shareholder approval, Veeva will become a public benefit corporation on Feb. 1, 2021, making it the first publicly traded company and largest-ever to convert to a PBC.
  • As part of a public benefit corporation, I know my contributions will help make a positive impact in the world.
  • This release contains forward-looking statements, including the statements regarding the expected impact and benefits of Veevas conversion to a Delaware public benefit corporation.
  • Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
    Veeva Systems Inc. owns other registered and unregistered trademarks.

Veeva Becomes First Public Company to Convert to a Public Benefit Corporation

Wednesday, January 13, 2021 - 9:54pm

With todays shareholder approval, Veeva will become a public benefit corporation on Feb. 1, 2021, making it the first publicly traded company and largest-ever to convert to a PBC.

Key Points: 
  • With todays shareholder approval, Veeva will become a public benefit corporation on Feb. 1, 2021, making it the first publicly traded company and largest-ever to convert to a PBC.
  • A key technology partner to the life sciences industry, Veeva is dedicated to customers mission to advance human health and wellbeing.
  • As part of a public benefit corporation, I know my contributions will help make a positive impact in the world.
  • This release contains forward-looking statements, including the statements regarding the expected impact and benefits of Veevas conversion to a Delaware public benefit corporation.

Prognos Health Caps Off Innovative Year With Award

Wednesday, December 16, 2020 - 2:31pm

NEW YORK, Dec. 16, 2020 /PRNewswire/ --Prognos Health, a leading clinically-focused healthcare analytics company, finishes a record year of new products and new partnerships with an award for product innovation.

Key Points: 
  • NEW YORK, Dec. 16, 2020 /PRNewswire/ --Prognos Health, a leading clinically-focused healthcare analytics company, finishes a record year of new products and new partnerships with an award for product innovation.
  • "Seeing prognosFACTOR receive this recognition is the culmination of a remarkable year for us at Prognos.
  • The launch of prognosFACTOR and the PM360 innovation award are the culmination of a year of significant advancements for Prognos Health.
  • Formed multiple strategic partnerships with key industry players to advance its mission to improve patient outcomes, including Livongo Health , Veeva Systems and Clarify Health Solutions .

Integra LifeSciences Selects Veeva Vault CDMS for Clinical Data Management

Tuesday, December 15, 2020 - 12:03pm

Veeva Systems (NYSE: VEEV) today announced that Integra LifeSciences, a global leader in regenerative technologies, neurosurgical, and extremity orthopedic solutions, has selected Veeva Vault CDMS to provide electronic data capture ( EDC ), coding , data cleaning , and reporting for future clinical trials.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced that Integra LifeSciences, a global leader in regenerative technologies, neurosurgical, and extremity orthopedic solutions, has selected Veeva Vault CDMS to provide electronic data capture ( EDC ), coding , data cleaning , and reporting for future clinical trials.
  • With Vault CDMS, Integra LifeSciences can shorten database build times for their studies.
  • Innovative MedTech companies like Integra LifeSciences are adopting Veeva Vault CDMS to drive greater flexibility and speed in trials, said Hugo Cervantes, vice president of strategy, Veeva Vault CDMS.
  • Organizations of all sizes across industries and therapeutic areas are accelerating clinical research with Vault CDMS, a suite of data management systems for todays clinical trials.

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Monday, December 14, 2020 - 10:00pm

Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline quality management on a single cloud platform.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline quality management on a single cloud platform.
  • The addition of Vault QMS builds upon the companys success with Veeva Vault QualityDocs for more efficient document control and management.
  • Together as part of the Veeva Vault Quality Suite , Samsung Biologics is bringing together quality process and content management for improved visibility across their global processes.
  • Vault QMS is a modern cloud application that unifies quality management and easily incorporates Samsung Biologics internal organization, pharmaceutical and biotech customers, contract manufacturers, and suppliers into one quality process.

Simbec-Orion Streamlines Trial Execution with Veeva Clinical Applications

Tuesday, December 8, 2020 - 12:03pm

Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents.
  • Veeva clinical applications will give Simbec-Orion real-time insights into studies across phases to accelerate trial execution.
  • Veeva provides the digital foundation to run complex clinical trials and keep studies on track, said Jim Kendall, chief information officer at Simbec-Orion.
  • Veeva Vault unifies clinical processes on a single platform to streamline information sharing with sponsors and ensure compliance with GCP requirements.

Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications

Tuesday, December 8, 2020 - 12:03pm

Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents.
  • Veeva clinical applications will give Simbec-Orion real-time insights into studies across phases to accelerate trial execution.
  • Veeva provides the digital foundation to run complex clinical trials and keep studies on track, said Jim Kendall, chief information officer at Simbec-Orion.
  • Veeva Vault unifies clinical processes on a single platform to streamline information sharing with sponsors and ensure compliance with GCP requirements.

Veeva Link Expands to 11 New Therapeutic Areas

Tuesday, November 17, 2020 - 12:03pm

Veeva Systems (NYSE: VEEV) today announced Veeva Link for 11 new therapeutic areas, including bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced Veeva Link for 11 new therapeutic areas, including bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology.
  • The addition of 11 new therapeutic areas builds upon the success of Veeva Link for Oncology , which is used today by 6 of the top 10 largest pharmaceutical companies.
  • Veeva Link provides real-time information on key people, including areas of expertise, peer collaborations, speaking engagements, social media activity, and clinical trial activity.
  • Veeva Link solutions for the 11 new therapeutic areas are planned for availability starting in March 2021.

Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market

Tuesday, November 17, 2020 - 12:03pm

Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (NYSE: BMY) is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers needs.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (NYSE: BMY) is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers needs.
  • Adoption of Vault PromoMats builds upon Bristol Myers Squibbs success with other Veeva Commercial Cloud applications, including Veeva CRM , Veeva CRM Engage Meeting , Veeva CRM Approved Email , Veeva CRM Events Management , and Veeva Vault MedComms .
  • Veeva gives Bristol Myers Squibb the commercial foundation for compliant content and multichannel engagement to drive a more tailored customer experience.
  • Learn how Vault PromoMats speeds compliant commercial content to market at the upcoming Veeva Commercial & Medical Europe Summit Online , Nov. 17-18, 2020.

Veeva Link Expands to 11 New Therapeutic Areas

Tuesday, November 17, 2020 - 7:03am

Veeva Systems (NYSE: VEEV) today announced Veeva Link for 11 new therapeutic areas, including bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology.

Key Points: 
  • Veeva Systems (NYSE: VEEV) today announced Veeva Link for 11 new therapeutic areas, including bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology.
  • The addition of 11 new therapeutic areas builds upon the success of Veeva Link for Oncology , which is used today by 6 of the top 10 largest pharmaceutical companies.
  • Veeva Link provides real-time information on key people, including areas of expertise, peer collaborations, speaking engagements, social media activity, and clinical trial activity.
  • Veeva Link solutions for the 11 new therapeutic areas are planned for availability starting in March 2021.